The Tweet Heard ‘Round the Pharmaceutical World: A Perspective On Pharmaceutical Drug Pricing

Posted by Alexis Kuchins on Oct 5, 2015 3:22:18 PM

A week ago, presidential candidate Hillary Clinton tweeted her intentions, if elected, to try to curb the rising costs of pharmaceuticals. The plan would place a monthly cap on the out-of-pocket cost that chronic pain patients would have to pay for prescription medications, a greater emphasis on bringing biotechnology-style drugs to the market, and encourage increased use of generic and imported drugs.

Read More

Topics: Competitive Intelligence, Innovation, Market Analysis, New Market Entry, Pharma, Scenario Analysis, Healthcare, Industry Convergence, Life Sciences, Product Positioning, Competitive Strategy

Companion Diagnostic Strategy: Who Bears Those Costs?

Posted by Alexis Kuchins on Sep 28, 2015 4:25:04 PM

The 2015 World CDx conference in Boston, Massachusetts brought together thought leaders from pharma, diagnostics, and companion diagnostic companies (CDx). This dynamic group of individuals engaged in a dialogue on areas such as next generation sequencing and companion diagnostics, precision medicine, and the regulatory landscape. In conversation with participants and presenters there was a consistent theme of seeking to understand companion diagnostic strategy and who will bear those costs.

Read More

Topics: Competitive Intelligence, Brand Insights, Innovation, Manufacturing/Industrial, Market Analysis, Medical Devices, Pharma, Scenario Analysis, Healthcare, Life Sciences

Automotive Disruption: Fines Doubled in Construction Zone

Posted by Robert Flynn on Sep 23, 2015 1:27:32 PM

While it was a boat that President Obama used to explore the Alaskan scenery, it is the automobile industry that should sit up and take notice. One anticipated result of the President’s trip, and ongoing international negotiations, is increased environmental regulation that would impact automobile manufacturers. Shifting consumer demand, expanding access to customer data, increased merger and acquisition activity and international regulatory changes are creating market uncertainty that needs to be explored and understood through robust scenario-based planning analysis. Shareholders will expect no less.

Read More

Topics: Competitive Intelligence, Consumer Goods, Brand Insights, Innovation, Market Analysis, New Market Entry, Scenario Analysis, Industry Convergence, Merger and Acquisition, Competitive Strategy

Honest lessons from the C-Suite

Posted by Leonard Fuld on Sep 16, 2015 9:14:57 AM

How often do you get down and talk about honest mistakes and irreverent strategies with a CEO?

Over the past year I have had the privilege to interview over a half dozen former CEOs from companies the likes of JP Morgan, Corning, Harrahs/Caesar’s Casinos and Pearson. All companies with a global reach and encountering one challenge or another. I’ve collected these interviews in a special section of this website, C-Suite Candor.

Read More

Topics: Competitive Intelligence, Consumer Goods, Brand Insights, Innovation, Manufacturing/Industrial, Market Analysis, New Market Entry, Scenario Analysis, Technology/Telecomm, Industry Convergence, Merger and Acquisition, Product Positioning, Competitive Strategy

The Future of Weddings: $50 billion up for grabs

Posted by Leonard Fuld on Sep 3, 2015 12:32:39 PM

Our daughter is about to be married and we look forward to this special day.

What we have not enjoyed is the process. I’ve never encountered such a complicated, messy and unsatisfying business in my entire life. When I say messy, I mean my wife and I have had to work with a tangle of over forty categories of vendors, from hotels, catering, bands, photographers, and so on.

Read More

Topics: Competitive Intelligence, Consumer Goods, Brand Insights, Innovation, Market Analysis, New Market Entry, Technology/Telecomm, Travel/Hospitality, Industry Convergence, Merger and Acquisition, Competitive Strategy

Deciphering the Alphabet

Posted by Robert Flynn on Sep 3, 2015 11:42:00 AM

Google’s transformation into Alphabet, announced in early August by CEO Larry Page, is on one hand inconsequential "Page Six" news and on the other the most momentous business event of the past decade. For companies in the technology and other sectors that Google has begun to explore, it’s a wake-up call as it signals Mr. Page's intention to continue to expand his conglomerate, increasing risk for companies across numerous industries. Fortunately, knowing that objective and deciphering the implications of this announcement, allows competitors time and opportunity to adjust their competitive strategy.

The recognition that Mr. Page and Google co-founder Sergey Brin have started and nurtured numerous side businesses including cloud computing, self-driving cars, life longevity, and even satellites brings a yawn from even the most casual observer. After all Elon Musk has gained fame as CEO of Tesla Motors (cars), CEO of SpaceX (rockets), and Chairman of SolarCity (power systems). And as far back as 1878 no less a man than Thomas Edison set the standard when he created General Electric – lightbulbs, steam turbines, locomotives, radio, toasters, even ovens. The conglomerate structure of Alphabet has a long, well-established tradition.

Read More

Topics: Competitive Intelligence, Consumer Goods, Brand Insights, Innovation, Market Analysis, New Market Entry, Technology/Telecomm, Industry Convergence, Merger and Acquisition, Competitive Strategy

Healthcare Industry Investors see Value in Owning Consumer Relationship

Posted by Jacob Golbitz on Aug 28, 2015 2:18:00 PM

On Monday the New York Times published a piece speculating on the next set of Unicorns, i.e., venture-backed start ups valued at $1 billion or more. An independent research firm developed the list using a proprietary "algorithm" to forecast their valuation. Not surprisingly, the list is dominated by technology companies, but a health care provider — One Medical Group — made the cut.

Read More

Topics: Competitive Intelligence, Brand Insights, Innovation, Market Analysis, New Market Entry, Pharma, Healthcare, Industry Convergence, Life Sciences, Competitive Strategy

The Post Office’s Business Transformation Strategy: Return to Sender

Posted by Nathaniel Emmons on Aug 27, 2015 10:35:00 AM

As a recent Wall Street Journal article reported, the U.S. Postal Service (USPS) is embarking on a new business strategy and entering the same-day delivery industry. The USPS is ill-equipped to effectively execute on this new competitive strategy and compete in the highly innovative same-day delivery industry. To see why this competitive strategy is ill-conceived, we must examine four key factors.

First, what inherent advantages does the USPS have that will enable it to succeed in the same day delivery market? The USPS has an expansive distribution channel, numerous physical locations, and a sophisticated delivery infrastructure throughout the country. For example, the USPS has 31,662 retail offices nationwide and 211,264 delivery vehicles at its disposal. Clearly, the USPS has the resources to succeed in the same-day delivery industry.

Read More

Topics: Competitive Intelligence, Value Chain Analysis, Brand Insights, Innovation, Market Analysis, Scenario Analysis, Competitive Strategy

Turning Managed Care Into Engaged Care Increases Value

Posted by Jacob Golbitz on Aug 20, 2015 2:46:00 PM

Within three weeks of Aetna’s agreement to acquire Humana for $37 billion, Anthem announced its agreement to purchase Cigna for $54.2 billion. If both of these deals go through, the number of major health insurance carriers in the U.S. will drop from five to three: Aetna, Anthem and UnitedHealth Group.

As Fuld + Co.’s SVP Diane Borska pointed out, “merger mania” is often driven by an innate sense among executives that larger companies with deeper resources will be better able to navigate a changing, dynamic market than smaller competitors; i.e., bigger is better.

Read More

Topics: Competitive Intelligence, Brand Insights, Innovation, Market Analysis, New Market Entry, Pharma, Healthcare, Industry Convergence, Life Sciences, Competitive Strategy

Sell-Offs and Mergers and Trades, Oh My!

Posted by Bruce Chin on Aug 18, 2015 11:44:41 AM

Current Trends in Big Pharma and What It Says About the Market

After unprecedented M&A activity in the last 20 years in Big Pharma, the trend of devolution isn’t just a topic that became popularised in Scotland. The pharmaceutical industry seems to be experiencing a similar trend. From the spin-off of AbbVie from Abbott in 2012 to Baxter’s specialised medicines spin-off, Baxalta, last month, the trend seems to be continuing. It continues with the swap of Novartis’s non-influenza vaccines business for the bulk of GSK’s oncology portfolio.

Read More

Topics: Competitive Intelligence, Market Analysis, Medical Devices, Pharma, Healthcare, Industry Convergence, Life Cycle Management, Life Sciences, Merger and Acquisition, Product Positioning, Competitive Strategy

Fuld + Company Blog

The material on this page draws on the research and experience of Fuld + Company thought leaders, consultants and others. Learn more about our expertise here.

Recent Posts

Request for Information

If you'd like someone at Fuld to contact you regarding your strategic competitive challenges, fill out the form below.